Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2% - Should You Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report)'s share price fell 2.2% on Wednesday . The company traded as low as $2.12 and last traded at $2.26. 8,111 shares were traded during trading, a decline of 37% from the average session volume of 12,897 shares. The stock had previously closed at $2.31.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.

Armata Pharmaceuticals Stock Up 4.0 %

The company has a market cap of $85.02 million, a price-to-earnings ratio of -1.04 and a beta of 0.80.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Equities analysts forecast that Armata Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

Institutional Trading of Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC grew its stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) by 80.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,777 shares of the company's stock after buying an additional 14,647 shares during the period. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent reporting period. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.